In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Will MDCPX outperform in the future? Get our overall rating based on a fundamental assessment of the pillars below.

The Fund seeks current income, long-term growth of capital and income and preservation of capital. The Fund invests at least 25% of its assets in equity securities and at least 25% of its assets in ...

Will AFMBX outperform in the future? Get our overall rating based on a fundamental assessment of the pillars below. American Funds announced in November 2025 that equity portfolio managers Mark Casey ...